Specific populations of urinary extracellular vesicles and proteins differentiate type 1 primary hyperoxaluria patients without and with nephrocalcinosis or kidney stones

Table 4 Number of urinary extracellular vesicles (EVs) derived from activated immune/inflammatory cells of primary hyperoxaluria type 1 patients without and with nephrocalcinosis (NC) or kidney stones (KS)

Urinary EVs/mg creatinine	Markers	Primary Hyperoxaluria Type 1 (PH1)			Statistical Results
Urinary EVs/mg creatinine	Markers	PH1 without NC or KS (n = 10)	PH1 with NC (n = 6)	PH1 with KS (n = 9)	p value	Q value
Total leukocyte-derived	CD45	11.3 (11.1, 11.5)	11.3 (11.1, 12.7)	10.2 (10.0, 10.9)	0.03	0.13*
Neutrophil-derived	CD15	11.9 (11.7, 12.5)	11.8 (11.1, 13.4)	10.6 (10.2, 11.8)	0.07	0.15*
B-lymphocyte-derived	CD19	11.4 (10.9, 12.2)	11.7 (10.7, 12.9)	9.8 (9.5, 10.9)	0.04	0.13*
T-lymphocyte-derived	CD3	11.2 (11.0, 11.5)	11.0 (10.8, 11.2)	10.1 (9.7, 10.8)	0.07	0.15*
Monocyte-derived	CD14	11.6 (10.7, 12.4)	12.6 (11.5, 12.9)	10.3 (10.0, 11.5)	0.03	0.13*
M1-macrophage-derived	CD68	11.7 (10.9, 11.9)	12.1 (11.1, 12.4)	10.5 (10.0, 11.0)	0.03	0.13*
M2-macrophage-derived	CD206	11.2 (10.8, 12.2)	11.2 (10.3, 12.4)	10.2 (9.2, 10.5)	0.11	0.17*
Plasma cell-derived	CD138 + CD319	10.7 (10.4, 11.8)	11.8 (10.6, 13.5)	10.2 (9.3, 10.9)	0.05	0.14*

Data are presented as median (25th and 75th percentile) of natural log of respective markers positive for urinary EVs/mg creatinine
^*False discovery rate (FDR) Q-value < 0.20 among PH1 patients groups

ISSN: 1750-1172